Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3936562 | Fertility and Sterility | 2009 | 4 Pages |
Abstract
Many patients who receive co-treatment with GnRH agonists (GnRH-a) during chemotherapy treatment preserve their ovarian function and are at risk of unintended pregnancies. Therefore, it is important to offer them effective contraception. Also, pregnancies occurring after cancer therapy in women who received GnRH-a are not associated with adverse neonatal outcomes.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Camil M.D., Ph.D., Aintzane M.D., Benet M.D., Ph.D., Magda M.D., Marta M.D., Juan M.D., Ph.D.,